首页 | 本学科首页   官方微博 | 高级检索  
     


Laparoscopic resection of a residual retroperitoneal tumor mass of nonseminomatous testicular germ cell tumors
Authors:?i?dem ?ztürk  Robert J. van Ginkel  Ruby M. Krol  Jourik A. Gietema  Hendrik S. Hofker  Harald J. Hoekstra
Affiliation:Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Abstract:

Background

Resection of a residual retroperitoneal tumor mass (RRRTM) is standard procedure after combination chemotherapy for metastatic nonseminomatous testicular germ cell tumors (NSTGCT).

Methods

At the University Medical Center Groningen, 79 consecutive patients with disseminated NSTGCT were treated with cisplatin combination chemotherapy between 2005 and 2007. Laparoscopic RRRTM was performed for patients with RRTM located less than 5?cm ventrally or laterally from the aorta or the vena cava. The 29 patients who fulfilled the criteria had a median age of 25?years (range, 16?C59?years). The stages of disease before chemotherapy treatment according to the Royal Marsden classification were 2A (n?=?6, 21%), 2B (n?=?14, 48%), 2C (n?=?3, 10%), and 4 with a lymph node status of N2 (n?=?6, 21%).

Results

The median duration of laparoscopy was 198?min (range, 122?C325?min). The median diameter of the RRTM was 21?mm (range, 11?C47?mm). Laparoscopic resection was successful for 25 patients (86%). Conversion was necessary for three patients (10%): two due to bleeding and one because of obesity. One nonplanned hand-assisted procedure (3%) also had to be performed. Histologic examination of the specimens showed fibrosis or necrosis in 12 patients (41%), mature teratoma in 16 patients (55%), and viable tumor in 1 patient (3%). The median hospital stay was 1?day (range, 1?C6?days). During a median follow-up period of 47?months (29?C70?months), one patient experienced an early relapse (1?month after the end of treatment) (4%).

Conclusion

For properly selected patients, laparoscopic resection of RRTM is an improvement in the combined treatment of disseminated NSTGCT and associated with a short hospital stay, minimal morbidity, rapid recovery, and a neat cosmetic result. Long-term data to prove oncologic efficacy are awaited.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号